Explore

Trendline Trendline
Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy
Trendline Trendline
FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Rollout
Trendline Trendline
FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months

FDA Delays Decision on Subcutaneous Leqembi for Alzheimer's by Three Months
Trendline Trendline
FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change
Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Trendline Trendline
Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes

Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes

Pfizer and Eli Lilly Report Q1 Earnings Amidst FDA Leadership Changes
Trendline Trendline
Novo Nordisk Reports Strong Q1 Performance Driven by Oral Wegovy Sales

Novo Nordisk Reports Strong Q1 Performance Driven by Oral Wegovy Sales

Novo Nordisk Reports Strong Q1 Performance Driven by Oral Wegovy Sales
Reuters Reuters
Amazon to carry Ozempic at US kiosks, offer same-day delivery

Amazon to carry Ozempic at US kiosks, offer same-day delivery

By Amina Niasse NEW YORK, May 7 (Reuters) - Amazon.com said on Thursday its pharmacy will stock Novo Nordisk's Ozempic pill to treat type 2 diabetes at its kiosks and offer same-day delivery of the drug Novo's Ozempic uses the active ingredient semaglutide to control blood sugar in people with type
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings